Back to Archived Journals » Orphan Drugs: Research and Reviews » Volume 5

The efficacy and safety of adalimumab in ocular inflammatory disease

Authors Arcinue CA, Durrani K, Artornsombudh P, Radwan A, Parikh R, Suelves A, Siddique S, Chang I, Preble J, Foster CS

Received 24 February 2015

Accepted for publication 29 June 2015

Published 31 August 2015 Volume 2015:5 Pages 69—74

DOI https://doi.org/10.2147/ODRR.S69582

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Lise Aagaard


Cheryl A Arcinue,1,2 Khayyam Durrani,1–3 Pichaporn Artornsombudh,1,2 Alaa Radwan,1,2 Ravi Parikh,1,2 Ana M Suelves,1,2 Sana S Siddique,1,2 Ian Chang,1,2 Janine M Preble,1,2 Charles Stephen Foster1–3

1Massachusetts Eye Research and Surgery Institution, 2Ocular Immunology and Uveitis Foundation, Cambridge, 3Department of Ophthalmology, Harvard Medical School, Boston, MA, USA

Objective: To evaluate the efficacy and safety of adalimumab in the management of ocular inflammation at our institution.
Methods: We performed a review of all patients with active ocular inflammation treated with adalimumab at our institution.
Results: Seventy eyes of 49 patients were reviewed. The mean duration of follow-up was 19.6 months. Therapy with an average of 2.1 immunomodulatory agents had been attempted prior to adalimumab therapy. At 1-year follow-up, adalimumab was effective in achieving quiescence in 33 eyes (47%). The most common side effects were injection-site reactions, arthralgias, and nausea, occurring in two patients each. Adalimumab was discontinued due to side effects in 12 patients.
Conclusion: These results suggest that adalimumab is an effective and safe therapeutic modality in ocular inflammation.

Keywords: uveitis, biologic response modifier, TNF-α, adverse effects, therapeutic outcomes, scleritis, peripheral ulcerative keratitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]